Development of Heart Muscle Regenerative Treatment for Ischemic Heart Disease
San Diego, California Oct 6, 2025 (Issuewire.com) – Jaan Biotherapeutics, Inc., a privately held biopharmaceutical company based in San Diego, California, focused on developing novel treatments for heart disease, has been awarded a Phase II SBIR grant of $2.89M from the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). The grant supports pre-clinical development of JBT-miR2, a microRNA targeting treatment, for the treatment of ischemic heart disease (IHD), following an acute myocardial infarction.
See press release: